186 related articles for article (PubMed ID: 36807080)
1. Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis.
Peeters G; Van Remoortel A; Nagels G; Van Schependom J; D'haeseleer M
Neurol Neuroimmunol Neuroinflamm; 2023 May; 10(3):. PubMed ID: 36807080
[TBL] [Abstract][Full Text] [Related]
2. Composite end points to assess delay of disability progression by MS treatments.
Zhang J; Waubant E; Cutter G; Wolinsky J; Leppert D
Mult Scler; 2014 Oct; 20(11):1494-501. PubMed ID: 24675040
[TBL] [Abstract][Full Text] [Related]
3. Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: A retrospective analysis from the CombiRx trial.
Petracca M; Cutter G; Cocozza S; Freeman L; Kangarlu J; Margoni M; Moro M; Krieger S; El Mendili MM; Droby A; Wolinsky JS; Lublin F; Inglese M
Eur J Neurol; 2022 Feb; 29(2):515-521. PubMed ID: 34695274
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.
Goldman MD; LaRocca NG; Rudick RA; Hudson LD; Chin PS; Francis GS; Jacobs A; Kapoor R; Matthews PM; Mowry EM; Balcer LJ; Panzara M; Phillips G; Uitdehaag BMJ; Cohen JA;
Neurology; 2019 Nov; 93(21):e1921-e1931. PubMed ID: 31641014
[TBL] [Abstract][Full Text] [Related]
5. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D
Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945
[TBL] [Abstract][Full Text] [Related]
6. Disability outcomes in early-stage African American and White people with multiple sclerosis.
Petracca M; Palladino R; Droby A; Kurz D; Graziano N; Wang K; Riley C; Howard J; Klineova S; Lublin F; Inglese M
Mult Scler Relat Disord; 2023 Jan; 69():104413. PubMed ID: 36399964
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Brazilian version of the patient-determined disease steps scale in persons with multiple sclerosis.
de David AC; Sasaki JE; Ramari C; Tauil CB; Moraes AG; Martins F; von Glehn F; Motl RW
Mult Scler Relat Disord; 2019 May; 30():208-214. PubMed ID: 30818129
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
Baeva ME; Tottenham I; Koch M; Camara-Lemarroy C
J Neuroimmunol; 2024 Feb; 387():578268. PubMed ID: 38157653
[TBL] [Abstract][Full Text] [Related]
9. The Multiple Sclerosis Functional Composite and Symbol Digit Modalities Test as outcome measures in pediatric multiple sclerosis.
Brenton JN; Koshiya H; Woolbright E; Goldman MD
Mult Scler J Exp Transl Clin; 2019; 5(2):2055217319846141. PubMed ID: 31065380
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness of coronavirus disease 2019 vaccination in patients with multiple sclerosis stratified by disease-modifying treatment.
De Troyer M; Van Remoortel A; Van Schependom J; Faille LD; D'hooghe MB; Peeters G; Nagels G; D'haeseleer M
Eur J Neurol; 2024 Jul; 31(7):e16300. PubMed ID: 38641878
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR
Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679
[TBL] [Abstract][Full Text] [Related]
14. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
[TBL] [Abstract][Full Text] [Related]
15. Single MRI-Based Volumetric Assessment in Clinical Practice Is Associated With MS-Related Disability.
D'hooghe MB; Gielen J; Van Remoortel A; D'haeseleer M; Peeters E; Cambron M; De Keyser J; Nagels G
J Magn Reson Imaging; 2019 May; 49(5):1312-1321. PubMed ID: 30597656
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
17. Sub-millimeter imaging of brain-free water for rapid volume assessment in atrophic brains.
Gao KC; Nair G; Cortese IC; Koretsky A; Reich DS
Neuroimage; 2014 Oct; 100():370-8. PubMed ID: 24945671
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Multiple Sclerosis Severity Score in a large US cohort.
Santoro JD; Waltz M; Aaen G; Belman A; Benson L; Gorman M; Goyal MS; Graves JS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rensel M; Rodriguez M; Schreiner T; Tillema JM; Waubant E; Weinstock-Guttman B; Hurtubise BF; Roalstad S; Rose J; Casper TC; Chitnis T;
Neurology; 2020 Sep; 95(13):e1844-e1853. PubMed ID: 32690790
[TBL] [Abstract][Full Text] [Related]
19. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
20. Information processing speed as a prognostic marker of physical impairment and progression in patients with multiple sclerosis.
Hechenberger S; Helmlinger B; Ropele S; Pirpamer L; Bachmaier G; Damulina A; Pichler A; Khalil M; Enzinger C; Pinter D
Mult Scler Relat Disord; 2022 Jan; 57():103353. PubMed ID: 35158430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
